GH Research PLC (NASDAQ:GHRS) Given Consensus Rating of “Moderate Buy” by Analysts

GH Research PLC (NASDAQ:GHRS) has earned a consensus rating of “Moderate Buy” from the eleven research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $40.1250.

Several analysts have issued reports on the company. HC Wainwright boosted their price target on GH Research from $35.00 to $70.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Citizens Jmp raised their price objective on GH Research from $39.00 to $42.00 and gave the stock a “market outperform” rating in a research note on Friday, March 6th. Guggenheim set a $34.00 price objective on GH Research and gave the company a “buy” rating in a research report on Tuesday, March 10th. Wolfe Research set a $39.00 target price on shares of GH Research in a report on Tuesday, January 6th. Finally, Needham & Company LLC raised their target price on shares of GH Research from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, March 6th.

Institutional Trading of GH Research

Institutional investors and hedge funds have recently modified their holdings of the company. Barclays PLC boosted its holdings in GH Research by 63.4% in the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after buying an additional 822 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new stake in GH Research during the fourth quarter valued at about $38,000. Osaic Holdings Inc. lifted its position in shares of GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after acquiring an additional 2,400 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in shares of GH Research in the second quarter valued at about $79,000. Finally, Virtus Investment Advisers LLC bought a new position in shares of GH Research in the second quarter worth about $89,000. 56.90% of the stock is currently owned by institutional investors.

GH Research Trading Up 1.1%

GHRS opened at $15.11 on Tuesday. The firm’s 50 day simple moving average is $15.71 and its two-hundred day simple moving average is $14.35. The company has a market capitalization of $937.27 million, a PE ratio of -18.89 and a beta of 1.00. GH Research has a 1-year low of $7.98 and a 1-year high of $19.51.

GH Research (NASDAQ:GHRS) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.06. Equities analysts forecast that GH Research will post -0.8 earnings per share for the current fiscal year.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.